S. Banerjee

发表

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

J. Haanen, K. Punie, S. Banerjee, 2021, ESMO open.

Prognostic gene expression signature for high-grade serous ovarian cancer

P. Fasching, A. Talhouk, J. Chang-Claude, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey

E. Felip, S. Choo, J. Haanen, 2021, ESMO Open.

Anti-NaPi 2 b antibody – drug conjugate lifastuzumab vedotin ( DNIB 0600 A ) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized , open-label , phase II study

A. Oza, M. Birrer, I. Ray-Coquard, 2018 .

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

A. Oza, M. Birrer, I. Ray-Coquard, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

José Luis Pérez-García, F. Lordick, G. Curigliano, 2021, ESMO Open.

Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service.

J. Larkin, O. Husson, W. T. van der Graaf, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

G. Rustin, H. Gabra, P. Vasey, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

J. Haanen, K. Punie, S. Banerjee, 2021, ESMO Open.

Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians

N. Pavlakis, M. IJzerman, L. Mileshkin, 2021, ESMO Open.

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.

M. Dowsett, I. Smith, S. Banerjee, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

H. Earl, J. Ledermann, G. Hall, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Y. Drew, S. Domchek, Young-Ae Park, 2019, Annals of Oncology.

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

M. Preusser, J. Tabernero, M. Petrova, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

A. Oza, J. Ledermann, E. Swisher, 2020 .

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.

S. Kaye, Susana Banerjee, A. George, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

M. Friedlander, C. Aghajanian, A. Leary, 2020, Annals of Oncology.

Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing.

C. Lord, S. Banerjee, S. Pettitt, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.

B. Monk, A. Oza, H. Hirte, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO Handbook on Translational Research

A. Scarpa, C. Sessa, S. Banerjee, 2015 .

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

A. Ashworth, S. Lakhani, J. Reis-Filho, 2006, Journal of Clinical Pathology.

New developments in the treatment of ovarian cancer--future perspectives.

Juanita Lopez, S. Kaye, Susana Banerjee, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.

M. Gore, S. Kaye, Susana Banerjee, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).

P. Beale, N. Bradshaw, L. Mileshkin, 2021, Gynecologic oncology.

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.

J. Ledermann, R. Glasspool, G. Rustin, 2020, Gynecologic oncology.

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

P. Jänne, P. Ascierto, P. V. Van Schil, 2020, Annals of Oncology.

Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).

P. Beale, M. Friedlander, N. Bradshaw, 2021, Gynecologic oncology.

723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

S. Pignata, M. Mirza, S. Banerjee, 2021, Annals of Oncology.

PO-457 Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers

R. Natrajan, K. Fenwick, F. Daley, 2018, ESMO Open.

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II

J. Haanen, K. Punie, S. Banerjee, 2021, ESMO Open.

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

U. Dafni, J. Tabernero, S. Choo, 2021, ESMO open.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

N. Tunariu, W. Brugger, D. Talbot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.

H. Hirte, C. Sessa, S. Kaye, 2011, Journal of Clinical Oncology.

Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience.

S. Banerjee, T. Eisen, C. Harper-wynne, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)

R. Glasspool, G. Jayson, I. McNeish, 2021, Annals of Oncology.

881PDIMPLEMENTATION OF ROUTINE BRCA GENE TESTING OF OVARIAN CANCER (OC) PATIENTS AT ROYAL MARSDEN HOSPITAL.

N. Rahman, H. Hanson, A. George, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.

S. Banerjee, J. Lima, Z. Ali, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.